Seattle Genetics
AcquiredPfizer: One of the world's premier biopharmaceutical companies
Bothell, United States · Founded 1998 · $1.0B raised
- Headquarters
- Bothell, Washington
- Employees
- 1001–5000
- Founded
- 1998
- Business Model
- B2B
- Website
- seagen.com
- Total Funding
- $1.0B
- Last Round
- $1.0B Corporate RoundSep 2020
- Rounds
- 4
- Acquired by
- PfizerDec 2023 · $43.0B
About
Seattle Genetics (later rebranded as Seagen) was a Bothell, Washington-based biotechnology company specializing in developing antibody-drug conjugates (ADCs) for cancer treatment. Founded in 1998, the company pioneered ADC technology, which links cancer-targeting antibodies to potent chemotherapy drugs, enabling precision delivery to tumor cells. Seagen was acquired by Pfizer in December 2023 for approximately $43 billion.
Summary
Seattle Genetics is a Biotechnology company based in Bothell, United States, founded in 1998. It has raised $1.0B in total across 4 rounds, most recently a $1.0B Corporate Round round in Sep 2020. Investors include Pfizer Ventures, Merck Life Sciences and J.P. Morgan.
Tech & App Stack
3 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Dec 2023
Sign up to see all 7 rounds
Angel through Acquisition — per-round amounts, valuations, and who invested in each round.
Investors
Acquisitions
Similar Companies
Biotechnology company focused on the development of antibody-drug conjugates for the treatment of...
Clinical-stage ophthalmic gene therapy company developing AAV-based treatments for rare and preva...
Sinotau develops, manufactures, and clinically advances innovative radiopharmaceuticals for diagn...
Clinical-stage biotechnology company pioneering GPCR drug discovery through its proprietary Nativ...
Clinical-stage biopharmaceutical company developing small-molecule therapies for serious diseases...
Confo Therapeutics develops small molecule and antibody-based GPCR-modulating medicines for metab...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/seattle-genetics"><img src="https://indexed.vc/api/badge/company/seattle-genetics" alt="Seattle Genetics on Indexed.vc" width="260" height="76" /></a>